PEP-Therapy owns IP rights for the exploitation of an innovative technology called CP&IP (Cell Penetrating & Interfering Peptides). Two major innovations have been combined in a single bi-functional peptide to target efficiently and accurately key cellular mechanisms involved in pathologies:
Optimized Cell Penetrating Peptides (CPP), as a "shuttle" to deliver drugs pharmaceutically active peptides into the cell and also into specific organelles;
Short Interfering peptides specifically designed to target relevant protein/protein interactions, thus blocking key mechanisms of diseases, with no effect on other physiological functions of the two proteins.
The combination of both technologies has led to the development of a unique technology with intracellular uptake and targeting, good in vivo stability and safety profile, and the versatility to address different intracellular targets, different pathways and multiple pathologies. PEP-Therapy has a number of products under development based on the CP&IP technology.